Thailand marked a significant change in its narcotics policy with the legalization of medical cannabis on February 18, 2019, becoming the first Southeast Asian country to do so. The “Narcotics Act of 2019,” which reformed the previous Narcotics Act of 1979, reclassified cannabis, removing it from the class-5 narcotics list but maintained the prohibition on recreational use. Only licensed research and development by public institutes and use with a medical certificate are permitted under this amendment.
In Maryland, adults 21 and older are allowed to consume cannabis on private property, although restrictions may apply depending on the landlord or management company’s policies. Renters should review their agreements closely, and hotel guests are advised to inquire about specific hotel policies regarding cannabis use, as most do not allow smoking in rooms.
In contrast, Texas maintains strict regulations against the possession and sale of cannabis, with the Texas Controlled Substances Act and the federal Controlled Substances Act listing it as a Schedule I substance. More information about the criminal penalties related to cannabis can be found on the Recreational Use page for Texas.
A study in Thailand using respondent-driven sampling methodology surveyed 485 adults who used cannabis for medical purposes in the past year. Face-to-face interviews with structured questionnaires were utilized to gather data, which helped in understanding the trends and acceptance of medical cannabis use.
Research indicates a decline in the prevalence of illicit drug use in Thailand from 2001 to 2003, with a stabilization in rates from 2003 onwards. Cannabis, kratom, and yaba continue to be the most commonly used substances, according to reports between 2001 and 2011.
The discussion around decriminalization has also reached Malaysia, where a study showed a significant portion of respondents (64.7%) expressed acceptance towards the decriminalization of medical marijuana. The study found associations between acceptance and various demographic factors such as age, gender, ethnicity, level of education, employment status, and tobacco use history.
The FDA’s stance on cannabis and cannabis-derived products, including cannabidiol (CBD), continues to evolve, with the agency regulating the production and marketing of hemp (Cannabis sativa L.) and its components.
The complexities of cannabis legalization, use, and regulation continue to evolve across different jurisdictions, reflecting a spectrum of acceptance and control.
Maryland Cannabis Administration
Medical Cannabis Use in Thailand
FDA Regulation of Cannabis
Medicinal Cannabis in Thailand
Medical Marijuana Decriminalization
Acceptance of Medical Marijuana Decriminalization
Cannabis & the Law in Texas
Illicit Substance Use in Thailand